| Symbol | AGNPF |
|---|---|
| Name | ALGERNON HEALTH INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | V5Z 4C2 Canada BC Suite 400 - 601 West Broadway Street |
| Telephone | +1 604-646-1553 |
| Fax | — |
| — | |
| Website | https://algernonpharmaceuticals.com/ |
| Incorporation | CA |
| Incorporated On | 2015 |
| Employees | — |
| Fiscal Year | 8/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | Smythe LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Canadian Securities Exchange |
| CIK | 0001642178 |
| Description | Algernon Pharmaceuticals is a Canadian healthcare company pioneering the establishment of Alzheimers screening, imaging and treatment medical clinics in North America, while also advancing clinical stage pharmaceuticals through the investigation of multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is also the parent company of a private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. Additional info from OTC: Additional info from OTC: |
No news found.